ArticleMolecular biology reports2026
Investigating YAP-dependent angiogenesis in glioblastoma.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGlioblastoma multiforme (GBM), the most prevalent and aggressive primary brain tumor, exhibits pronounced angiogenesis. YAP/TAZ have been found as critical candidates in vascular sprouting, vascular barrier formation, and angiogenesis. Furthermore, the dysregulation of YAP/TAZ is reported to be implicated in the development and poor prognosis of several malignancies. METHODS AND
resultsIn this study, the relationship between the Hippo and VEGF signaling pathways was examined in GBM. Initially, co-expression networks for GBM and healthy tissues were constructed using WGCNA, identifying potential modules enriched in Hippo and VEGF pathway genes. Differentially expressed genes (DEGs) and transcription factors were analyzed for pathway overlap and enrichment. Subsequently, the Hippo pathway transducer Yap1 was knocked out in C6 GBM cells using CRISPR/Cas9, and a rat GBM model was developed. Angiogenic effects were assessed using CAM assay, immunohistochemistry (IHC), and qPCR. Two transcription factors, including RELA and NF-κB were identified as the shared members of the Hippo and VEGF signaling pathways. In the next step, the analysis through CAM assay supported a significant decrease in the length of vessels in the treated group with conditioned medium of Yap1-KO C6 cells. Additionally, the IHC results have suggested the reduced density and neoformation of the vessels in the Yap1-KO rat GBM models. Moreover, the knockout of Yap1 resulted in a remarkable decrease in Vegf expression in the rat GBM tumors.
conclusionsThe results suggest a notable role for the Hippo pathway transducer Yap1 in the angiogenic procedures and highlight the potential of targeting Hippo-YAP1 signaling to enhance anti-angiogenic strategies in GBM.
Indexed as
Identifiers
42507234What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.